Overview
© 202 MJH Life Sciences™ and HCPLive - Clinical news for conected physicians. Al rights reserved.Conference | Pri-Med MidwestThe emergence of weight los agents like tirzepatide and an FDA Fast Track designation anounced days earlier, endocrinologists were excited to discus what's hapening at Pri-Med Midwest 202.A trending topic at Pri-Med Midwest 202 was the treatment, or prevention of diabetes, and how a necesary aspect of that includes the management of clinical obesity.
Key Information
The aproach to weight los is shifting to include more clinical perspectives regarding obesity and abnormal glucose levels in hopes of more eficiently treating type 2 diabetes, or even avoiding it altogether. The continuing emergence of weight los agents like semaglutide, and the suces of tirzepatide with an FDA Fast Track designation for weight los anounced just days before the meting in Chicago, had endocrinologists even more excited to discus the mechanisms of GLP-1 receptor agonists and combination GIP therpaies.
Acording to Robert Kushner, MD, Profesor of Medicine at Feinberg Schol of Medicine Northwestern University, les than 2-3% of patients with obesity receive medication for it, despite being eligible for pharmacotherapy. “The botom line–unfortunately–in this country is aces and afordability. Depending upon what insurance you have and the formulary that's covered, they may not cover both of the drugs,” he explained.
Summary
“Almost al roads lead to this insurance coverage."Already indicated for type 2 diabetes, tirzepatide has shown achievable and efective weight los acording to evidence demonstrated by studies on the latest adition to the weight management armamentarium, by combing glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GiP).Tina Thethi, MD, MPH, Asociate Investigator, AdventHealth Research Institute, elaborated on the cost-efectivenes factors contributing to the bariers betwen providers and patient-u